Skip to main content

Table 8 Office blood pressure on treatment with placebo or different daily doses of rostafuroxin in previously untreated patients

From: Main results of the Ouabain and Adducin for Specific Intervention on Sodium in Hypertension Trial (OASIS-HT): a randomized placebo-controlled phase-2 dose-finding study of rostafuroxin

  

Mean level ± SD

at end of treatment period

Mean difference

(95% CI)

P-values

 

N

Placebo

Rostafuroxin

Rostafuroxin minus

placebo

Treatment

effect

Carryover

effect

Period

effect

Systolic pressure, mm Hg

       

   0.05 mg

57

141.1 ± 11.8

145.8 ± 12.8

4.59 (1.43 to 7.74)

0.005

0.319

0.174

   0.15 mg

41

140.3 ± 12.1

140.7 ± 13.8

0.26 (-4.10 to 4.61)

0.906

0.312

0.062

   0.5 mg

38

142.1 ± 15.5

142.9 ± 13.4

0.72 (-4.01 to 5.45)

0.759

0.271

0.530

   1.5 mg

41

140.9 ± 11.8

142.9 ± 12.6

2.02 (-1.46 to 5.51)

0.248

0.414

0.959

   5.0 mg

48

139.1 ± 9.9

142.1 ± 12.9

2.89 (-0.54 to 6.31)

0.096

0.477

0.113

   All doses

225

140.7 ± 12.1

143.0 ± 13.1

2.35 (0.71 to 4.00)

0.005

0.674

0.044

Diastolic pressure, mm Hg

       

   0.05 mg

57

87.4 ± 8.4

89.2 ± 8.5

1.78 (-0.45 to 4.01)

0.115

0.951

0.417

   0.15 mg

41

88.0 ± 8.5

88.3 ± 9.9

0.29 (-2.30 to 2.88)

0.823

0.836

0.252

   0.5 mg

38

87.8 ± 8.6

88.6 ± 8.2

0.80 (-2.61 to 4.21)

0.636

0.112

0.873

   1.5 mg

41

88.0 ± 8.9

90.8 ± 6.4

2.82 (0.51 to 5.12)

0.018

0.344

0.191

   5.0 mg

48

86.7 ± 8.0

88.4 ± 7.8

1.74 (-1.17 to 4.66)

0.235

0.510

0.173

   All doses

225

87.5 ± 8.4

89.1 ± 8.2

1.53 (0.37 to 2.69)

0.010

0.714

0.033

  1. Mean differences were estimated using analysis of variance with sequence, subjects nested within sequence, and period and treatment group entered as covariables. Abbreviations: N = number of patients; SD, standard deviation; CI, confidence interval.